STOCK TITAN

Zymeworks Inc. - $ZYME STOCK NEWS

Welcome to our dedicated page for Zymeworks news (Ticker: $ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zymeworks's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zymeworks's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.72%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.6%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
none
Zymeworks Inc.

NYSE:ZYME

ZYME Rankings

ZYME Stock Data

649.23M
41.59M
4.49%
96.15%
7.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
MIDDLETOWN

About ZYME

zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.